The Open Microbiology Journal

Content list available at: https://openmicrobiologyjournal.com

Supplementary Material

Network of Interaction among *Enterobacter species* and *Klebsiella pneumonia* Clinical Isolates and the Antibiotic Resistance Pattern at Cape Coast : Network of Interaction among *Enterobacter species* and *Klebsiella pneumonia*

Kwame Kumi Asare[1,*], Jennifer Mbata[2], Samuel Amoah[3], Peter Bilatam Mayeem[4], Felicity Bentsi-Enchill[2] and Yeboah Kwaku Opoku[2]

[1]*Department of Biomedical Science, School of Allied Health Sciences, College of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana*
[2]*Department of Biology Education, Faculty of Science Education, University of Education, Winneba, Ghana*
[3]*Laboratory Unit, University of Cape Coast Hospital, Cape Coast*
[4]*Offinso College of Education, Ashanti Region, Ghana*

SUPPLEMENTARY INFORMATION

Table S1. The antibiotics zone of inhibitions among the resistant *K. pneumonia* and *Enterobacter species* isolated from 2014 to 2020.

			Zone of Antibiotic inhibitions among pathogenic bacteria isolates, Median (range), mm											
	2014	2015	2016	2017	2018	2019	2020	2014	2015	2016	2017	2018	2019	2020
			Klebsiella pneumonia							Enterobacter species				
Antibiotics	**(n=7)**	**(n=17)**	**(n=22)**	**(n=27)**	**(n=4)**	**(n=12)**	**(n=3)**	**(n=20)**	**(n=7)**	**(n=19)**	**(n=22)**	**(n=9)**	**(n=39)**	**(n=9)**
Ceftriaxone	10 (0-12)	12 (0-14)		10 (0-10)	8 (0-11)	10 (4-12)	10 (4-11)			12 (0-13)	10 (4-12)	10 (0-11)	12 (0-13)	12 (2-16)
Levofloxacin	9 (2-13)		9 (2-11)	10 (4-12)		10 (0-12)		12 (7-16)		12 (2-16)	10 (2-14)		12 (5-15)	
Ceftazidime	10 (0-12)	10 (0-13)	10 (5-12)	12 (3-16)		10 (6-14)	10 (0-12)		12 (4-15)	13 (4-16)	12 (2-16)	11 (8-14)	13 (8-14)	10 (0-11)
Ciprofloxacin	10 (0-11)	11 (3-12)	10 (4-12)	10 (4-12)		10 (4-12)		12 (8-15)	12 (0-14)	11 (5-15)		12 (0-14)	10 (0-13)	12 (9-16)
Gentamicin	10 (4-12)	10 (4-11)	11 (8-14)	12 (7-15)		10 (0-10)		12 (3-16)	12 (7-16)	10 (4-12)	10 (6-12)		13 (4-16)	
Cefuroxime	12 (3-14)	10 (5-12)	12 (0-14)	10 (2-12)			13 (4-17)			12 (3-14)	12 (7-16)	12 (3-16)	12 (0-13)	12 (3-14)
Chloramphenicol	13 (0-16)	10 (3-16)	10 (6-14)	10 (0-12)		10 (6-14)		10 (0-12)	12 (0-14)	12 (2-14)	12 (3-14)	12 (0-14)	12 (2-16)	12 (2-14)
Ampicillin	11 (3-13)	12 (0-17)	12 (2-16)	13 (3-15)		12 (5-13)	10 (2-14)		9 (0-10)	10 (6-14)	10 (2-14)	12 (5-14)	11 (6-13)	12 (0-12)
Trimethoprim/	10 (0-13)	10 (4-11)	11 (3-13)	10 (2-12)		10 (0-12)		12 (2-16)	12 (0-15)	12 (0-14)	12 (8-15)	12 (2-14)	12 (0-14)	11 (5-15)
Sulfamethoxazole	11 (6-13)	12 (0-13)	12 (0-13)	11 (3-12)		14 (8-16)		12 (0-14)	12 (2-16)	12 (0-14)	12 (0-14)	12 (7-15)	12 (3-16)	11 (5-15)
Nitrofurantoin	10 (5-12)	10 (4-12)	10 (2-14)	10 (0-13)	10 (3-16)	10 (5-12)		9 (0-10)	10 (4-12)	12 (3-14)	10 (4-11)	13 (4-16)	11 (3-12)	12 (8-15)

			Zone of Antibiotic inhibitions among pathogenic bacteria isolates, Median (range), mm											
	2014	**2015**	**2016**	**2017**	**2018**	**2019**	**2020**	**2014**	**2015**	**2016**	**2017**	**2018**	**2019**	**2020**
			Klebsiella pneumonia							**Enterobacter species**				
Antibiotics	**(n=7)**	**(n=17)**	**(n=22)**	**(n=27)**	**(n=4)**	**(n=12)**	**(n=3)**	**(n=20)**	**(n=7)**	**(n=19)**	**(n=22)**	**(n=9)**	**(n=39)**	**(n=9)**
Amoxicillin/	10 (2-12)				10 (6-12)					12 (2-14)		12 (0-14)		12 (0-14)
Clavulanic Acid	14 (9-16)				12 (7-16)					10 (6-14)		12 (5-14)		12 (8-15)
Piperacillin/	10 (0-12)		12 (0-14)	10 (4-12)	12 (3-14)	10 (2-14)				12 (3-16)	10 (5-12)	10 (5-12)	10 (4-12)	12 (3-16)
Tazobactam	12 (2-16)		10 (4-12)	10 (2-14)	10 (2-14)	12 (2-16)				12 (0-14)	10 (2-12)	10 (4-12)	10 (2-14)	12 (0-14)
Cefuroxime	10 (0-12)	14 (9-16)	10 (2-14)	12 (2-16)	10 (2-14)	10 (2-14)	10 (2-12)			12 (0-17)	14 (9-16)	12 (5-13)	12 (2-16)	12 (0-13)
Norfloxacin	10 (4-12)	10 (0-12)	12 (2-16)	12 (0-14)		13 (4-17)	11 (3-12)	12 (0-14)	12 (7-16)	10 (4-11)	10 (0-12)		12 (0-13)	
Tetracycline	13 (5-15)	12 (2-16)	11 (3-12)	12 (8-15)		10 (6-14)	10 (0-13)	12 (0-14)	11 (0-15)	12 (0-13)	12 (2-16)	12 (0-14)	12 (2-16)	13 (0-17)
Nalidixic Acid	10 (6-14)		10 (6-14)	8 (3-10)		13 (7-15)	7 (0-11)	10 (4-12)	12 (2-14)	10 (0-12)	12 (0-14)	12 (3-16)	13 (4-16)	
Augmentin	12 (0-17)	10 (0-12)	10 (0-10)	10 (2-12)	10 (4-11)	10 (0-13)		12 (8-15)	10 (6-12)	13 (4-17)	12 (0-17)	14 (9-16)	10 (2-14)	10 (2-14)
Gemifloxacin	10 (4-11)							12 (0-14)	11(5-12)			12 (8-14)		8 (0-11)
Ampicillin-sulbactam	12 (0-13)							12 (8-12)						
Ceftazidime		10 (6-12)	12 (7-16)	10 (2-14)	10 (5-12)	10 (2-14)	10 (4-11)	10 (0-11)	12 (2-16)	12 (8-15)	12 (0-13)	10 (4-12)	12 (8-15)	12 (-16)
Meropenem		10 (0-13)	14 (9-16)	12 (0-13)		8 (3-10)	12 (0-13)		12 (5-13)	12 (3-16)	12 (5-15)	12 (5-14)	12 (4-15)	9 (0-13)
Vancomycin		12 (2-16)	10 (2-14)	11 (6-13)		10 (2-12)	10 (0-12)		12 (3-16)	12 (0-14)	13 (8-14)	10 (5-12)	12 (0-14)	12 (2-16)
N-acetylcysteine										12 (0-14)		12 (7-15)		
Cefdinir										12 (0-17)				
Cephalothin										10 (4-11)	12 (2-16)	12 (0-14)	12 (5-13)	
Penicillin			10 (5-12)	10 (2-14)					13 (4-16)					
Erythromycin			10 (2-12)						10 (0-10)					
Ofloxacin				10 (6-14)							12 (8-14)			
Amikacin				10 (0-10)									12 (5-13)	

n, number of isolated tested.

© 2022 Asare *et al*.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.